SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing a significant pullback, driven by renewed concerns over potential tariff escalations with China, sparking volatility. The community is actively debating whether this dip presents a buying opportunity or signals a deeper correction, with some anticipating a "V"-shaped recovery while others brace for further downside. This is happening amid discussions around government shutdowns, delayed CPI data, and the Federal Reserve's potential policy response.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing volatility amid concerns about potential tariff increases on Chinese goods, sparked by comments from a former US president. Community sentiment is mixed, with some traders anticipating a deeper correction and others expecting a quick rebound, while some are mentioning potential market manipulation. Traders are closely monitoring key technical levels and the VIX, with many citing the potential for a "V-shaped" recovery.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals is trending due to a recently announced private placement of up to $104.5 million, exciting investors with the potential for growth. Community chatter highlights the stock's low float and speculation about a short squeeze, with some drawing comparisons to similar situations like $SPRB. The overall sentiment suggests anticipation for significant upward movement, with some traders setting ambitious price targets.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP is trending amidst volatility, with community discussions focusing on its potential as a key player in the rare earth market following government support and strategic partnerships. A possible Trump administration stake in critical metals and tighter export controls in China on rare earth are being closely watched. Community members are weighing potential impact on the stock, alongside technical analyses and potential breakout patterns.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing volatility, driven by market reactions to broader economic concerns, including potential tariffs. The community is actively discussing dip-buying opportunities and potential manipulation, with some expressing frustration over ETH's performance relative to other assets. Despite the current uncertainty, some anticipate a future breakout and continue to emphasize the long-term potential of ETH and its underlying technology.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 2x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders assess potential market volatility amidst economic uncertainty and geopolitical tensions, with some anticipating a significant spike. Community members are actively discussing potential catalysts such as government shutdowns and are weighing the impact of various economic indicators. The conversation also highlights UVXY's complex relationship with the broader market, particularly its role as a hedge against potential downturns.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to increased investor interest in antimony as a critical mineral, particularly following news of potential government support and contracts, with community members discussing price targets and the company's growth potential. The stock is seen as a key player in North American antimony production amid global supply chain concerns and geopolitical factors. Some traders are concerned about short-term volatility and profit-taking, while long-term investors remain bullish.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

SG Blocks Inc

SGBX is trending due to a mix of factors, including potential catalysts related to feasibility expansion, UK pilot updates, and regulatory announcements. The community is actively discussing float mechanics, short squeeze potential given the low share count, and the impact of a recent offering on the stock's price. Technical analysis and identification of potential breakout patterns are also contributing to the heightened interest in SGBX.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the crypto community discusses its recent price movement, with some anticipating a breakout past key resistance levels. Community members are pointing to potential ETF approvals and its role as 'digital silver' as possible catalysts. Traders are actively watching technical indicators and discussing potential price targets amidst broader market fluctuations.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after Q1 results showed significant revenue growth, driven by its high-performance computing (HPC) hosting business and a major lease agreement with CoreWeave. Community members are focused on the potential for a short squeeze, fueled by high short interest and institutional validation, while anticipating further expansion and new hyperscaler deals. Bullish sentiment is strong, with some eyeing a longer-term target, while others are wary of potential pullbacks after the recent surge.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright raised its price target on AnaptysBio (ANAB) to $59 from $38 on Tuesday, following the company's announcement of its plan to split its business into two.The analyst kept a ‘Buy’ rating on the shares. The new price target implies a potential upside of about 154% to the stock’s closing price on Monday.AnaptysBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations">stated </a>on Tuesday that its board of directors approved plans to explore separating its business into two independent, publicly traded companies. Upon completion of the split, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and Imsidolimab with Vanda, with a focus on protecting and returning their value, the company said.The royalty management company is expected to require minimal infrastructure and staff, and will operate under a new name, it added.Meanwhile, the other company, referred to as Biopharma Co., will focus on biopharmaceutical operations, including the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, such as Rosnilimab, ANB033, and ANB101. After the split, Biopharma Co. will launch with adequate capital to fund operations for at least two years and will also operate under a new name, the company stated.The separation is expected to be completed by the end of 2026. Anaptys CEO Daniel Faga is expected to continue as CEO of the biopharma company.Shares of the company traded 30% higher on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANAB">ANAB stock</a> rose from ‘bullish’ to ‘extremely bullish territory’ over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_12_21_38_PM_png_239792a64d.webp" alt="ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they now expect the stock to crater.<stembedurl>https://stocktwits.com/CommercialREbroker/message/630482537</stembedurl>ANAB stock has more than doubled this year but dropped nearly 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

H.C. Wainwright’s new price target of $59 implies a potential upside of about 154% to the stock’s closing price on Monday. 

Equity

Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug peresolimab and mixed results from its obesity pill candidate orforglipron weighed on investor appetite.&nbsp;In the 72-week ATTAIN-1 study, orforglipron met its main goal of superior weight reduction over placebo across all three tested doses. Patients on the highest 36 mg dose lost an average of 27.3 pounds, or 12.4% of their body weight, compared with just 2.2 pounds, or 0.9%, on placebo. Almost six in ten people shed at least 10% of their weight, and about four in ten lost 15% or more.Among the 1,127 participants with prediabetes at enrollment, up to 91% of those on treatment achieved near-normal blood sugar levels at 72 weeks, compared with 42% on placebo. The trial also showed improvements in waist circumference, cholesterol, triglycerides, blood pressure, and inflammation markers.&nbsp;However, weight loss plateaued for most patients. Researchers noted that despite the 72-week duration, weight reduction was not greater than in the prior Phase 2 trial, possibly due to differences in trial design, including greater geographic diversity and a higher proportion of male participants.The main side effects were mild-to-moderate stomach issues such as nausea, constipation, diarrhea and vomiting, with between 5.3% and 10.3% of patients stopping treatment, compared with 2.7% on placebo. No liver safety signals were seen.Orforglipron, licensed from Chugai in 2018, is also in late-stage studies for type 2 diabetes, sleep apnea and hypertension. Lilly said more than 4,500 people are enrolled in its Phase 3 ATTAIN program and that a filing in diabetes is planned for 2026.TD Cowen Downplays Peresolimab ReactionSeparately, TD Cowen analysts said Tuesday that the market reaction to Eli Lilly’s peresolimab data “seems excessive,” noting that AnaptysBio’s rival PD-1 agonist rosnilimab has reported no malignancies in any of its trials.Lilly halted development of peresolimab, an experimental PD-1 agonist for rheumatoid arthritis, after a Phase IIb study raised safety concerns. While the drug was superior to placebo at week 12 across several key endpoints, its efficacy was not clearly differentiated from existing therapies.&nbsp;In addition, malignancies were reported in patients receiving peresolimab, including two cases in each of the 1,000 mg and 400 mg dose groups through week 12, and four more cases by week 60, compared with none in the placebo arm.&nbsp;Reports of possible major cardiovascular events also weighed on the program’s benefit–risk profile and contributed to the decision to stop development.On Stocktwits, retail sentiment for Lilly was ‘bearish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/LLY">Lilly’s stock</a> has declined 0.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Why Is Eli Lilly’s Stock Slipping Premarket?

The drugmaker’s oral GLP-1 pill orforglipron showed mixed data in a Phase 3 trial, and regulatory filing for obesity is targeted as early as next year.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from testing their experimental rheumatoid arthritis medication rosnilimab.The stock closed 7.6% higher at $23.52 on Tuesday, extending gains by another 5.1% to $24.71 in after-hours trading.A trial involving 424 patients proved that rosnilimab, a PD-1+ T cell depleter and agonist, delivered similar effectiveness to JAK inhibitors when administered&nbsp;monthly.&nbsp;Patients saw significant disease activity improvements through reductions in the Clinical Disease Activity Index (CDAI) and ACR70 response rates, which lasted for six months.The treatment-free period of up to two months showed sustained patient responses, which signals the possibility for longer dosing intervals.&nbsp;According to the company, no serious treatment-related adverse events appeared during the study, and the drug demonstrated superior tolerability compared to existing biologics and JAK inhibitors.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.One user&nbsp;suggested the stock was being "pumped" and speculated that a direct offering might follow.&nbsp;<stembedurl>https://stocktwits.com/Yukinvestor/message/616705356</stembedurl>Another user said they expected the updated data to disappoint and anticipated a potential offering.<stembedurl>https://stocktwits.com/Yukinvestor/message/616686959</stembedurl>The stock has risen 76.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo seen displayed on a smartphone screen on a desk next to a Macbook in Athens, Greece on November 12, 2022. (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering

The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects.

What’s the role of generative AI in drug discovery?

Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist Vanda Pharmaceuticals and Anaptys Announce...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021.&nbsp;The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis, commonly known as eczema.Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_12_at_5_59_31_PM_c4fa8def22.png" alt="Screenshot 2024-12-12 at 5.59.31 PM.png" width="1318" height="324"><figcaption>ANAB sentiment meter and message volume on Dec 12 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for AnaptysBio plunged into ‘extremely bearish’ levels before the bell on Thursday, following a 20% jump in message volume in the previous session.<stembedurl>https://stocktwits.com/SurdifiedStocks/message/596025184</stembedurl><stembedurl>https://stocktwits.com/Blossom_Tradez/message/595998006</stembedurl>AnaptysBio stated that it would redirect its resources and capital toward other investigational autoimmune therapies.&nbsp;The company plans to report top-line Phase 2b data for rosnilimab in rheumatoid arthritis by February 2025 and Phase 2 data for ulcerative colitis in the first quarter of 2026.Wall Street analysts quickly adjusted their outlooks. H.C. Wainwright downgraded the stock to ‘Neutral’ from ‘Buy,’ slashing its price target from $52 to $19.&nbsp;The brokerage expressed disappointment but not surprise, citing the high-risk nature of the ANB032 program. It also lowered its probability of success estimates for rosnilimab in rheumatoid arthritis from 50% to 40% and for ulcerative colitis from 40% to 30%.Wells Fargo analyst Derek Archila lowered the firm’s price target for AnaptysBio to $40 from $56 but maintained an ‘Overweight’ rating.&nbsp;Archila noted that while the Phase 2b trial’s failure aligns with their bear-case scenario, the shares’ current valuation offers a favorable risk/reward profile ahead of upcoming Phase 2 data releases.AnaptysBio's stock has lost over 28% year-to-date as of Wednesday’s close, with the latest developments adding further pressure on its stock performance and investor confidence.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen with a computer wallpaper in the background in Athens, Greece on May 5, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated

Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

Latest Ratings for ANAB
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
 View More...

What Analysts Are Saying About AnaptysBio Stock

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

ANAB
AnaptysBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANAB News

ANABAnaptysBio Inc